Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7800550 | 0.89 | HTT (0.57) | HTTMAPTHCAR3ALDH1A1MAPK1 | |
| SCHEMBL2334056 | 0.89 | HTT (0.72) | HTTMAPTHCAR3ALDH1A1MAPK1 | |
| SCHEMBL10790188 | 0.86 | HTT (0.68) | HTTMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL7811924 | 0.85 | HTT (0.56) | HTTMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL7805730 | 0.84 | HTT (0.78) | HTTMAPTHCAR3ALDH1A1MAPK1 | |
| SCHEMBL11526803 | 0.83 | HTT (0.71) | HTTMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL3060501 | 0.82 | HCAR3 (0.61) | HTTMAPTHCAR3ALDH1A1MAPK1 | |
| SCHEMBL12983948 | 0.81 | HTT (0.60) | HTTMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL3717161 | 0.81 | HCAR3 (0.50) | HTTMAPTHCAR3ALDH1A1L3MBTL1 | |
| SCHEMBL30625382 | 0.78 | HTT (0.57) | HTTMAPTALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1465882-A4 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1465882-A2 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003060078-A9 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| WO-2003060078-A2 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20010052156-A1 | DYES | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 2001-12-20 | — | — | US | disclosed |
| US-20010005914-A1 | OXIDATION DYES | ANDREAS J. BITTNER | 2001-07-05 | — | — | US | disclosed |
| EP-0912160-A2 | OXIDATION DYES | Hans Schwarzkopf GmbH & Co. KG (DE) | 1999-05-06 | — | — | EP | disclosed |
| EP-0910332-A2 | DYES | Hans Schwarzkopf GmbH & Co. KG (DE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998001106-A2 | OXIDATION DYES | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998001105-A2 | DYES | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010052156-A1 | DYES | KRT18, OPRD1, HTR1D | HTT 1345/4885MAPT 4151/4885HCAR3 69/4885 |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | HTT 3314/4885MAPT 4111/4885HCAR3 79/4885 |
| US-20010005914-A1 | OXIDATION DYES | AOC1, CBR3, KRT18 | HTT 3880/4885MAPT 3633/4885HCAR3 795/4885 |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | HTT 3314/4885MAPT 4111/4885HCAR3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.